Good Clinical Practice Guide
Results 1 to 1 of 1

Thread: EU Clinical Trials New Regulation Important Consultations HAVE YOUR SAY

  1. #1

    EU Clinical Trials New Regulation Important Consultations HAVE YOUR SAY

    EU Clinical Trials New Regulation Major developments on Risk Proportionate Guidance; Trial Results for Laypersons; Definitions of IMP and AMPs; Ethical Considerations for Minors.
    HAVE YOUR SAY

    The following guidance which has been developed in preparation for the implementation of the Clinical Trial Regulation (EU) No 536/2014 is currently out for public consultation from 1 June 2016 to 31 August 2016 by the European Commission:

    Risk Proportionate Approaches in Clinical Trials
    The main objective of this document is to provide further information on how a risk proportionate approach can be implemented in clinical trials and highlights areas within the clinical trials Regulation which support such adaptations.

    Please submit your contributions by e-mail to:SANTE-B4-GL-risk-proportionate-approach@ec.europa.eu

    Summary of Clinical Trial Results for Laypersons
    Article 37 of the Clinical trial Regulation (EU) No 536/2014 requires that sponsors provide a summary of clinical trial results in the EU Portal and Database, in a format understandable to laypersons. The main objective of this document is to provide recommendations and templates for the production of a summary of clinical trial results for laypersons by sponsors and investigators, in accordance with Annex V of the EU Clinical Trials Regulation.

    Please submit your contributions by e-mail to: SANTE-B4-GL-results-laypersons@ec.europa.eu

    Definition of Investigational Medicinal Products (IMPs) and use of Auxiliary Medicinal Products (AMPs)" (previously called "Guidance on Investigational Medicinal Products (IMPS) and Non-Investigational Medicinal Products (NIMPs))
    The main objective of this revision is to align it with the Clinical Trials Regulation and with the latest (scientific) insights.

    Please submit your contributions by e-mail to: SANTE-B4-GL-IMP-AMP@ec.europa.eu

    Ethical Considerations for Clinical Trials on Medicinal products conducted with Minors
    The main objective of this revision is to align the document with the Clinical Trials Regulation (EU) No 536/2014 and with the latest (scientific) insights on research with children.

    Please submit your contributions by e-mail to: SANTE-B4-GL-Ethics-Minors@ec.europa.eu

    The link below will direct you to the European Commission website:
    http://ec.europa.eu/health/human-use...s/index_en.htm

    Do not send your contributions to the MHRA, please send to the address provided by the Commission.
    Last edited by MHRA Super Moderator; 8th Jul 2016 at 01:55 PM. Reason: correct header

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •